News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Aurobindo has one of the most enduring generics ecosystems among peers
This marks Glenmark's first synthetic decapeptide injectable approval
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Subscribe To Our Newsletter & Stay Updated
